Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron Boster

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Plos One|March 22, 2013
Iron is a sensitive biomarker for inflammation in multiple sclerosis lesionsVeela Mehta, Wei Pei, Grant Yang, et al.
Neurology and Therapy|February 18, 2017
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims DatabaseAaron Boster, Jacqueline Nicholas, Ning Wu, et al.
Pharmacoeconomics - Open|February 22, 2018
Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims DataJacqueline Nicholas, Aaron Boster, Ning Wu, et al.
The Lancet. Neurology|January 22, 2008
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinicianAaron Boster, Gilles Edan, Elliott Frohman, et al.
Archives of Neurology|July 14, 2010
Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imagingDavid Pitt, Aaron Boster, Wei Pei, et al.
International Journal of MS Care|September 1, 2020
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS SurveyAnn D Bass, Bart Van Wijmeersch, Lori Mayer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2014
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialTomas Olsson, Aaron Boster, Óscar Fernández, et al.
Drugs|November 20, 2008
Disease-modifying agents for multiple sclerosis: recent advances and future prospectsTil Menge, Martin S Weber, Bernhard Hemmer, et al.
Multiple Sclerosis and Related Disorders|October 12, 2020
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosisTimothy L Vollmer, Jeffrey A Cohen, Enrique Alvarez, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 8, 2021
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 yearsDana Horáková, Aaron Boster, Antonio Bertolotto, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Plos One|March 22, 2013
Iron is a sensitive biomarker for inflammation in multiple sclerosis lesionsVeela Mehta, Wei Pei, Grant Yang, et al.
Neurology and Therapy|February 18, 2017
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims DatabaseAaron Boster, Jacqueline Nicholas, Ning Wu, et al.
Pharmacoeconomics - Open|February 22, 2018
Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims DataJacqueline Nicholas, Aaron Boster, Ning Wu, et al.
The Lancet. Neurology|January 22, 2008
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinicianAaron Boster, Gilles Edan, Elliott Frohman, et al.
Archives of Neurology|July 14, 2010
Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imagingDavid Pitt, Aaron Boster, Wei Pei, et al.
International Journal of MS Care|September 1, 2020
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS SurveyAnn D Bass, Bart Van Wijmeersch, Lori Mayer, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2014
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialTomas Olsson, Aaron Boster, Óscar Fernández, et al.
Drugs|November 20, 2008
Disease-modifying agents for multiple sclerosis: recent advances and future prospectsTil Menge, Martin S Weber, Bernhard Hemmer, et al.
Multiple Sclerosis and Related Disorders|October 12, 2020
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosisTimothy L Vollmer, Jeffrey A Cohen, Enrique Alvarez, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 8, 2021
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 yearsDana Horáková, Aaron Boster, Antonio Bertolotto, et al.
Pageof 3